Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

  • Details

ClinicalTrials.gov ID: NCT02756364
Diagnosis Type: NA
USOR Number: 17047

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Tucson

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen

  • Details

ClinicalTrials.gov ID: NCT03173092
Diagnosis Type: NA
USOR Number: 17081

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Carcinoid

Clinical Trial at: Arizona Oncology - Tucson

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Arizona Oncology - Phoenix

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Skin Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Tucson

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Glendale

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

  • Details

ClinicalTrials.gov ID: NCT02756364
Diagnosis Type: NA
USOR Number: 17047

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Melanoma

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

  • Details

ClinicalTrials.gov ID: NCT03273153
Diagnosis Type: NA
USOR Number: 17013

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Skin Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Arizona Oncology - Phoenix

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Carcinoid

Clinical Trial at: Arizona Oncology - Phoenix

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Tucson

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Carcinoid

Clinical Trial at: Arizona Oncology - Sedona

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Melanoma

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

  • Details

ClinicalTrials.gov ID: NCT03273153
Diagnosis Type: NA
USOR Number: 17013

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Carcinoid

Clinical Trial at: Arizona Oncology - Tucson

A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

  • Details

ClinicalTrials.gov ID: NCT03284424
Diagnosis Type: NA
USOR Number: 17060

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Phoenix

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Pages